|
|
Vaccine Detail
|
S-268019 |
| Vaccine Information |
- Vaccine Name: S-268019
- Target Pathogen: SARS-CoV-2
- Target Disease: COVID-19
- Manufacturer: Shionogi
- Vaccine Ontology ID: VO_0005096
- Type: Subunit vaccine
- Status: Clinical trial
- Host Species for Licensed Use: Human
- Immunization Route: Intramuscular injection (i.m.)
- Description: The vaccine S-268019-b is a severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike (S)-protein vaccine consisting of full-length recombinant SARS-CoV-2 S-protein (S-910823) as antigen, mixed with the squalene-based adjuvant A-910823 (Hashimoto et al., 2022)
|
| Host Response |
|
Monkey Response
- Immune Response: Two weeks after the second dosing, dose-dependent humoral immune responses were observed with neutralizing antibody titers being comparable to that of human convalescent plasma. (Hashimoto et al., 2022)
- Side Effects: No adverse clinical signs or weight loss associated with the vaccine were observed, suggesting safety of the vaccine in cynomolgus monkeys.
|
| References |
Hashimoto et al., 2022: Masayuki Hashimoto 1, Noriyo Nagata 2, Tomoyuki Homma 3, Hiroki Maeda 4, Keiji Dohi 5, Naomi M Seki 6, Ken Yoshihara 7, Naoko Iwata-Yoshikawa 8, Nozomi Shiwa-Sudo 9, Yusuke Sakai 10, Masayuki Shirakura 11, Noriko Kishida 12, Tomoko Arita 13, Yasushi Suzuki 14, Shinji Watanabe 15, Hideki Asanuma 16, Takuhiro Sonoyama 17, Tadaki Suzuki 18, Shinya Omoto 19, Hideki Hasegawa 20. Immunogenicity and protective efficacy of SARS-CoV-2 recombinant S-protein vaccine S-268019-b in cynomolgus monkeys. . 2022; ; . [PubMed: 35691872].
|
|
